

AMENDMENTS TO THE CLAIMS

Please replace all prior versions, and listings, of claims in the application with the following list of claims, in which insertions are indicated by underlining and deletions are indicated by strikeouts or double bracketing.

1. - 91. (Canceled)

92. (Currently Amended) [[The]] A method of claim 43, wherein for treating a subject having a B-cell malignancy resistant to therapy with an antibody specific for a surface antigen selected from CD19, CD20, and CD22, wherein cells of the malignancy have low or no baseline expression of the surface antigen, the method comprising:

administering to the subject the immunostimulatory CpG oligonucleotide [[is]] ODN 2006 (SEQ ID NO:729) comprising a backbone modification and an unmethylated C, in an effective amount to upregulate expression of the surface antigen by the cells; and

administering to the subject an antibody specific for the upregulated surface antigen, in an effective amount to treat the subject.

93. (Currently Amended) [[The]] A method of claim 1, wherein for treating a subject having a B-cell malignancy, wherein cells of the B-cell malignancy have low or no baseline expression of CD20, the method comprising:

administering to the subject the immunostimulatory CpG oligonucleotide [[is]] ODN 2006 (SEQ ID NO:729) comprising a backbone modification and an unmethylated C, in an effective amount to upregulate expression of CD20 by the cells; and

administering to the subject an antibody specific for CD20, in an effective amount to treat the subject.

94. - 98. (Canceled)

99. (Currently Amended) [[The]] A method of claim 24, wherein for treating a subject having a marginal zone lymphoma or B-cell chronic lymphocytic leukemia, wherein cells of the lymphoma or leukemia have low or no baseline expression of an antigen selected from CD19 and CD22, the method comprising:

administering to the subject the immunostimulatory CpG oligonucleotide [[is]] ODN 2006 (SEQ ID NO:729) comprising a backbone modification and an unmethylated C, in an effective amount to upregulate expression of the antigen by the cells of the lymphoma or leukemia; and
administering to the subject an antibody specific for the upregulated antigen, in an effective amount to treat the subject.

100. - 103. (Canceled)

104. (Currently Amended) [[The]] A method of claim 34, wherein for treating a subject having a B-cell malignancy, wherein cells of the malignancy upregulate expression of a surface antigen selected from CD19, CD20, and CD22, in response to immunostimulatory CpG oligonucleotide, the method comprising:

isolating malignant B cells from the subject;
identifying a surface antigen selected from CD19, CD20, and CD22, the expression of which can be upregulated in response to immunostimulatory CpG oligonucleotide, wherein the surface antigen is expressed by the malignant B cells in an amount lower than that of normal B cells;
administering to the subject the immunostimulatory CpG oligonucleotide [[is]] ODN 2006 (SEQ ID NO:729) comprising a backbone modification and an unmethylated C, in an effective amount to upregulate expression of the surface antigen by the cells; and
administering to the subject an antibody specific for the upregulated surface antigen, in an amount effective to treat the subject.